Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2005

View Archived Issues

Ropinirole improves restless legs syndrome symptoms

Tipifarnib pharmacodynamics studied in patients with hematologic malignancies

Prana receives U.K. clearance for PLACQUE study of PBT-1 for Alzheimer's

Adolor to copromote Arixtra with GlaxoSmithKline

Expanded indication for Bexxar in relapsed low-grade or follicular NHL

IND accepted for phase I study of CPP-109 for treating cocaine addition

Vigabatrin induces abstinence in methamphetamine, cocaine addiction

Novo Nordisk makes progress with NovoSeven

IND filing for clinical testing of Probactrix for pouchitis

Xsira, new name for Norak Biosciences

Milestone in Alnylam/Merck collaboration

Israeli approval for Azilect

GLP-1 analogue decreases weight gain and food intake in rats

Researchers at AstraZeneca claim HER2 inhibitors

Scientists at elbion describe PDE4 inhibitors in patent literature

Novel agents for Alzheimer's disease in early development at GSK

Platelet antiaggregatory agents disclosed by Daiichi

Bristol-Myers Squibb patent covers new agents for hepatitis C infection

PTP-1B inhibitors prepared and tested at Sankyo

Squalamine selected for CMA Pilot 2 program

StemCells files IND for human neural stem cell transplant for Batten disease

Dimethaid Research and Solvay finalize Canadian Pennsaid agreement

ACAM-2000 smallpox vaccine granted fast track designation

European approval for duloxetine hydrochloride for major depressive episodes

Approvable letter for Sanvar IR for esophageal variceal bleeding

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...